Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGT NASDAQ:GHRS NASDAQ:LNTH NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$38.87-4.0%$35.02$10.38▼$43.73$6.92B0.343.18 million shs2.05 million shsGHRSGH Research$26.51-2.5%$23.21$11.32▼$28.96$1.87B1.28232,039 shs128,457 shsLNTHLantheus$105.64-0.3%$100.71$47.25▼$111.86$6.90B-0.06903,661 shs942,439 shsSRRKScholar Rock$56.71-2.1%$49.42$27.07▼$58.49$6.94B0.671.73 million shs828,811 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-4.05%+0.47%+23.87%+6.87%+273.75%GHRSGH Research-2.54%-1.85%+30.21%+68.64%+71.25%LNTHLantheus-0.33%-3.87%+5.39%+31.08%+26.53%SRRKScholar Rock-2.12%+3.33%+28.62%+13.51%+53.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$38.87-4.0%$35.02$10.38▼$43.73$6.92B0.343.18 million shs2.05 million shsGHRSGH Research$26.51-2.5%$23.21$11.32▼$28.96$1.87B1.28232,039 shs128,457 shsLNTHLantheus$105.64-0.3%$100.71$47.25▼$111.86$6.90B-0.06903,661 shs942,439 shsSRRKScholar Rock$56.71-2.1%$49.42$27.07▼$58.49$6.94B0.671.73 million shs828,811 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-4.05%+0.47%+23.87%+6.87%+273.75%GHRSGH Research-2.54%-1.85%+30.21%+68.64%+71.25%LNTHLantheus-0.33%-3.87%+5.39%+31.08%+26.53%SRRKScholar Rock-2.12%+3.33%+28.62%+13.51%+53.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.86Moderate Buy$43.7312.50% UpsideGHRSGH Research 2.73Moderate Buy$40.3852.30% UpsideLNTHLantheus 2.73Moderate Buy$108.292.50% UpsideSRRKScholar Rock 3.12Buy$56.00-1.25% DownsideCurrent Analyst Ratings BreakdownLatest GHRS, SRRK, COGT, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/8/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/18/2026SRRKScholar Rock Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/AGHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/ALNTHLantheus$1.54B4.46$6.36 per share16.60$16.43 per share6.43SRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)GHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)LNTHLantheus$233.56M$4.1525.4619.64N/A18.05%29.32%15.00%8/5/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)Latest GHRS, SRRK, COGT, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026GHRSGH Research-$0.31N/AN/AN/AN/AN/A8/5/2026Q2 2026LNTHLantheus$1.30N/AN/AN/A$363.03 millionN/A8/5/2026Q2 2026SRRKScholar Rock-$0.84N/AN/AN/A$3.33 millionN/A8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent Biosciences0.4115.1415.14GHRSGH ResearchN/A34.1334.13LNTHLantheus0.472.832.64SRRKScholar Rock0.718.648.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AGHRSGH Research56.90%LNTHLantheus99.06%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences6.59%GHRSGH Research41.60%LNTHLantheus1.70%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableGHRSGH Research1068.61 million40.07 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableSRRKScholar Rock140119.83 million103.89 millionOptionableGHRS, SRRK, COGT, and LNTH HeadlinesRecent News About These CompaniesSG Americas Securities LLC Cuts Stake in Scholar Rock Holding Corporation $SRRKJuly 9 at 4:07 AM | marketbeat.comKristina Burow Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8 at 5:11 AM | americanbankingnews.comJeffrey Flier Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8 at 5:11 AM | americanbankingnews.comJoshua Reed Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8 at 5:11 AM | americanbankingnews.comKatie Peng Sells 5,446 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 8 at 4:27 AM | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Director Michael Gilman Sells 2,544 Shares of StockJuly 7, 2026 | americanbankingnews.comMichael Gilman Sells 2,544 Shares of Scholar Rock (NASDAQ:SRRK) StockJuly 7, 2026 | insidertrades.comPictet Asset Management Holding SA Cuts Stake in Scholar Rock Holding Corporation $SRRKJuly 1, 2026 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of "Buy" by BrokeragesJuly 1, 2026 | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsJuly 1, 2026 | marketbeat.comScholar Rock (NASDAQ:SRRK) Reaches New 12-Month High - Still a Buy?June 30, 2026 | americanbankingnews.comScholar Rock: New Treatment Boost For SMA Patients -- With September PDUFAJune 25, 2026 | seekingalpha.comScholar Rock (NASDAQ:SRRK) Reaches New 52-Week High - What's Next?June 24, 2026 | marketbeat.comScholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHDJune 22, 2026 | finance.yahoo.comCasdin Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRKJune 18, 2026 | marketbeat.comArmistice Capital LLC Takes Position in Scholar Rock Holding Corporation $SRRKJune 18, 2026 | marketbeat.comGranahan Investment Management LLC Raises Stock Position in Scholar Rock Holding Corporation $SRRKJune 17, 2026 | marketbeat.comPolar Capital Holdings Plc Buys 527,929 Shares of Scholar Rock Holding Corporation $SRRKJune 17, 2026 | marketbeat.comWhy Scholar Rock’s Workforce Expansion Is Drawing Attention Across BiotechnologyJune 15, 2026 | kalkinemedia.comKFirst Turn Management LLC Buys Shares of 459,727 Scholar Rock Holding Corporation $SRRKJune 14, 2026 | marketbeat.comScholar Rock Holding Corporation $SRRK is Eventide Asset Management LLC's 9th Largest PositionJune 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, SRRK, COGT, and LNTH Company DescriptionsCogent Biosciences NASDAQ:COGT$38.87 -1.64 (-4.05%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$38.90 +0.03 (+0.07%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.GH Research NASDAQ:GHRS$26.51 -0.69 (-2.54%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$27.00 +0.49 (+1.86%) As of 07/10/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Lantheus NASDAQ:LNTH$105.64 -0.35 (-0.33%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$104.80 -0.84 (-0.80%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Scholar Rock NASDAQ:SRRK$56.71 -1.23 (-2.12%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$56.52 -0.19 (-0.34%) As of 07/10/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
